DSIP (Delta Sleep-Inducing Peptide)

A nine-amino-acid neuropeptide first isolated from rabbit venous blood in 1977. DSIP promotes NREM delta-wave sleep in a manner that differs mechanistically from sedative-hypnotics: it appears to shift the sleep-wake neuroendocrine state rather than directly suppressing neuronal excitability. Confirmed to occur endogenously in human plasma and CSF. A modest human trial base from the 1980s–1990s shows weak-to-moderate sleep improvement in chronic insomniacs; modern controlled data are absent. Not FDA-approved; no active clinical trials as of 2026-05-09. Currently sees use in peptide clinics and compounding pharmacies with minimal evidence base.

Identity

PubChem CID: 68816
ChEMBL ID: CHEMBL2104403
WHO INN: emideltide
Amino acid sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (single-letter: WAGGDASGE)
Molecular formula: C₃₅H₄₈N₁₀O₁₅
Molecular weight: 848.82 Da
Class: endogenous neuropeptide (nonapeptide); biologic
DrugBank ID: not assigned as of 2026-05-09 needs-canonical-id

Discovery and early characterisation

DSIP was characterised by Schoenenberger and Monnier at the University of Basel in 1977 ¹. The original experimental paradigm was heterochronic: the intralaminar thalamic area of donor rabbits was electrically stimulated to induce a hypnogenic (sleep-promoting) state, extracorporeal dialysates of cerebral venous blood were collected and fractionated, and the active fraction was infused intraventricularly into recipient rabbits. The fraction reproducibly induced EEG delta-wave activity in the recipients. The active component was isolated and identified as a nonapeptide with sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. The 1977 PNAS paper focused on demonstrating biological specificity of synthetic DSIP versus nine related peptides and breakdown products; full sequence confirmation was reported in the 1978 follow-up ².

A 1978 follow-up confirmed the complete sequence and demonstrated that synthetic DSIP produced a mean 35% increase in delta EEG activity in the rabbit neocortex ². The active peptide was named “delta sleep-inducing peptide” on the basis of its EEG effect, not a confirmed receptor. The acronym DSIP was established in this paper.

Endogenous status in humans

DSIP is confirmed endogenous in humans. Graf, Kastin, and Fischman (1984) demonstrated free DSIP in human cerebrospinal fluid and plasma by gel and HPLC chromatography, with a distinct elution peak matching synthetic DSIP ³. The same group detected DSIP-like immunoreactivity in human breast milk at approximately 30 ng/mL in colostrum, declining to ~10 ng/mL in mature milk, with circadian variation (afternoon peak) ⁴. Most of the immunoreactivity was in a molecular form larger than the nonapeptide, though DSIP itself was confirmed by HPLC. These findings confirm the peptide is not merely a pharmacological tool but part of the endogenous sleep-neuroendocrine system, though the biological role of circulating DSIP-like material in breast milk remains speculative.

However, the physiological role of circulating DSIP remains uncertain: it is unclear whether plasma DSIP crosses the blood-brain barrier at relevant concentrations, and whether circulating levels fluctuate in a sleep-stage-dependent manner in free-living humans has not been adequately characterised.

Mechanism of action

What is established: DSIP attenuates HPA-axis output. In a randomised double-blind crossover study in 11 healthy male volunteers, 25 nmol/kg synthetic DSIP IV produced a significant reduction in plasma ACTH-like immunoreactivity lasting at least 3 hours post-infusion; plasma cortisol was unaffected ⁵. This HPA-axis inhibitory effect is the most pharmacologically documented human action of the peptide.

What is inferred, not established: Older literature associates DSIP with modulation of GABA, serotonin, dopamine, and noradrenaline systems. These associations come primarily from animal microinjection studies and indirect measurements; no specific receptor for DSIP has been identified, and no binding affinity values exist in ChEMBL or comparable bioactivity databases for DSIP against these targets. The multi-neurotransmitter framing should be treated as correlational until a molecular target is characterised.

How it differs from sedative-hypnotics: DSIP does not appear to act by enhancing GABA-A receptor-mediated inhibitory post-synaptic currents, which is the mechanism of benzodiazepines and Z-drugs (zolpidem, zopiclone). The 1981 healthy-volunteer study specifically noted no sedation “in the classic pharmacologic way” despite improvements in sleep ⁶. This distinction — sleep architecture promotion vs. pharmacological sedation — is the primary rationale for interest in DSIP as a more physiological sleep agent.

no-mechanism — No specific receptor or molecular target for DSIP has been confirmed. The mechanistic picture is incomplete: the peptide promotes sleep and suppresses ACTH, but the receptor(s) mediating these effects are unknown. Whether the HPA-axis effect is primary (and sleep follows from reduced stress-hormone tone) or whether there are direct hypothalamic sleep-circuit effects is not resolved.

Preclinical evidence

The original rabbit intraventricular infusion studies (n=58 rabbits total; 11 receiving synthetic DSIP, 23 receiving PEP-Long analogues, 11 receiving PEP-Short breakdown products, 13 controls) showed significant and specific enhancement of delta and spindle EEG patterns by synthetic DSIP versus all comparators, using Wilcoxon-Mann-Whitney statistical tests (p<0.01 approximately 10 min post-infusion, sustained for the remainder of the 94-min experiment) ¹. The neocortical delta increase was 53.9% and limbic delta increase was 39.3% relative to controls. The 1978 sequence-confirmation study using 61 rabbits found a mean 35% increase in both neocortical and limbic cortex delta activity for synthetic DSIP vs CSF-like solution controls ². Subsequent animal work across multiple groups during the 1980s replicated sleep-promoting effects in several rodent models, though with variable effect sizes. No lifespan extension data exists for DSIP in any model organism. No DrugAge entry for DSIP as of 2026-05-09.

Dimension	Status
Sleep-promoting effect conserved in humans?	yes (limited small-study evidence)
HPA-axis attenuation in humans?	yes (Bjartell 1989, n=11)
Replicated with modern methods?	no

Human evidence

Five small double-blind placebo-controlled studies were conducted between 1981 and 1992 (including two 1981 studies by Schneider-Helmert). All used IV administration at 25 nmol/kg. None reported p-values in their abstracts; effect sizes are not directly comparable across studies.

Study	n	Design	Dose / Route	Key sleep finding	Conclusion
Schneider-Helmert et al. 1981a ⁶	6 healthy volunteers	Crossover, DB, placebo-controlled	25 nmol/kg IV (morning)	Sleep increased 59% (median total sleep time) vs placebo within 130 min; delayed effects: shorter sleep onset latency, reduced stage 1, better sleep efficiency next night	”DSIP in humans is also efficacious by sustaining natural sleep functions”; no sedation in the classic pharmacologic sense
Schneider-Helmert & Schoenenberger 1981b ⁷	6 middle-aged chronic insomniacs	Acute IV administration	25 nmol/kg IV	Longer sleep duration and higher quality; slightly more REM sleep; sleep-promoting effects from 1–6 h post-injection; no daytime sedation	”DSIP has a normalizing influence on human sleep regulation”
Monti et al. 1987 ⁸	not specified in abstract	Double-blind crossover; 4 nights	25 nmol/kg IV × 4 nights	Decreased nocturnal awakenings, NREM latency, total waking time; increased total sleep and NREM (stage 2); no significant differences vs baseline or placebo for most measures	”Sleep improvement under DSIP treatment is of little clinical significance”
Schneider-Helmert 1987 ⁹	14 middle-aged chronic insomniacs	DB, 7 successive nights	25 nmol/kg IV	”Substantially improved night sleep” with first and repeated doses; effects maintained first post-treatment placebo night; daytime alertness and performance increased significantly	”Demonstrates efficacy of DSIP for treatment of impaired sleep and daytime functions”
Bes et al. 1992 ¹⁰	16 chronic insomniacs	Double-blind matched-pairs parallel-groups	25 nmol/kg IV × 3 consecutive afternoons	Higher sleep efficiency and shorter sleep latency vs placebo; one subjective tiredness measure decreased within DSIP group; no change in subjective sleep quality or other measures	”Short-term treatment of chronic insomnia with DSIP is not likely to be of major therapeutic benefit”

Overall assessment: The double-blind data show a consistent directional signal (sleep efficiency up, latency down) but weak effect sizes and lack of statistical significance in most endpoints. The two rigorous conclusions are contradictory in framing (Schneider-Helmert 1987 positive; Monti 1987 and Bes 1992 negative). All studies used IV administration — an impractical route for chronic sleep treatment. No modern polysomnography-endpoint study using subcutaneous or intranasal delivery exists.

Route-of-administration limitation: IV is not a viable chronic delivery route for a sleep intervention. Intranasal peptide delivery can bypass the blood-brain barrier and is feasible for neuropeptides of this size, but no DSIP intranasal study has been published. Subcutaneous administration (common in peptide clinic use) lacks pharmacokinetic characterisation. This is a major translation barrier.

needs-human-replication — No double-blind RCT with modern polysomnographic endpoints, intranasal or subcutaneous route, and adequate statistical power exists. The 1980s–1990s literature base is the entirety of the controlled human evidence.

Comparison with sedative-hypnotics

DSIP is described in the literature as a “sleep-promoting substance” rather than a sedative-hypnotic, a distinction with potential clinical relevance for older adults:

Sedative-hypnotics (zolpidem, benzodiazepines): enhance GABA-A receptor chloride conductance → broad neuronal inhibition → rapid sleep onset, but also next-day cognitive impairment, fall risk, and habituation. Long-term use associated with cognitive decline and dependence.
DSIP (proposed mode): attenuates HPA-axis, may normalise the neuroendocrine sleep-wake signal without direct GABAergic sedation. The 1981 study reported no conventional sedation; participants were not impaired.

This distinction is mechanistically plausible but not definitively established. No head-to-head comparison with a sedative-hypnotic has been conducted, and the absence of sedation could reflect insufficient dose or systemic exposure rather than a fundamentally different mechanism.

Aging relevance

DSIP has no direct evidence linking it to lifespan or hallmark-level biology. The aging-relevance case is indirect:

Sleep quality declines with age: slow-wave sleep amplitude and duration decrease from middle age; sleep fragmentation increases. Poor sleep quality in older adults is associated with elevated cortisol, increased inflammatory cytokines, impaired memory consolidation, and accelerated cognitive decline.
HPA-axis hyperactivation in aging: cortisol rises with age and excessive HPA-axis tone is implicated in hippocampal atrophy, immunosenescence, and metabolic dysregulation. DSIP’s documented ACTH-suppressing effect in 11 young healthy male volunteers ⁵ is mechanistically relevant to this pathway, though no aging-context study has tested DSIP on HPA-axis biomarkers in older adults.
Sleep as an intervention target: multiple aging hallmarks are worsened by chronic sleep disruption via inflammatory and metabolic pathways. A sleep-promoting agent operating without sedation could theoretically interrupt this cycle without the cognitive-impairment liability of current hypnotics.

None of these links have been established with direct evidence. DSIP’s aging relevance is speculative at present.

Why interest waned — and current revival

The 1980s–1990s literature reached largely equivocal conclusions. The IV-only delivery route and the absence of a confirmed receptor made DSIP difficult to develop as a pharmaceutical. By the mid-1990s research had largely shifted to melatonin, orexin antagonists, and GABAergic agents with cleaner pharmacology.

Current revival is driven by the broader peptide-clinic / compounding-pharmacy trend: DSIP is included in multi-peptide protocols (e.g., PCAC 503A bulk lists) and marketed for sleep improvement and stress reduction. The evidence base underlying this use is identical to the 1980s studies — no new controlled data has been generated. PubMed returned zero results for DSIP sleep aging from 2020–2026.

Limitations and knowledge gaps

No confirmed molecular target. The mechanism is correlational.
All controlled trials used IV administration — impractical for chronic use; subcutaneous and intranasal PK are not characterised.
Small n throughout — the largest study had 16 subjects.
No modern placebo-controlled RCT. The evidence base has not been updated in approximately 30 years.
No aging-specific data. All human studies targeted chronic insomniacs, not older adults with age-related sleep changes.
Blood-brain barrier penetration of exogenous DSIP is uncertain — the endogenous peptide is present in CSF, but whether IV or SC administration achieves sufficient CNS access is not established.
No DrugAge entry. No lifespan or healthspan evidence in any model organism.
0 active clinical trials (ClinicalTrials.gov v2 API, 2026-05-09). needs-human-replication

Footnotes

doi:10.1073/pnas.74.3.1282 · Schoenenberger GA, Monnier M · Proc Natl Acad Sci USA 1977 Mar;74(3):1282–1286 · n=58 rabbits total (11 DSIP, 23 PEP-Long analogues, 11 PEP-Short breakdown products, 13 controls) · in vivo (intraventricular infusion, double-blind) · characterisation of DSIP biological specificity: only synthetic DSIP showed significant and specific enhancement of delta and spindle EEG patterns; neocortical delta increase 53.9%, limbic delta increase 39.3% vs controls; p<0.01 approximately 10 min post-infusion; local PDF: via a local paper archive (PMC430668) ↩ ↩²
doi:10.1007/BF00581575 · Schoenenberger GA, Maier PF, Tobler HJ, Wilson K, Monnier M · Pflugers Arch 1978;376(2):119–129 · n=61 rabbits · in vivo (intraventricular infusion) · amino-acid analysis, sequence, synthesis and activity confirmed; mean 35% increase in both neocortical and limbic cortex delta EEG activity with synthetic DSIP vs controls receiving CSF-like solution; PMID: 568769 ↩ ↩² ↩³
doi:10.1016/s0091-3057(84)80016-7 · Graf MV, Kastin AJ, Fischman AJ · Pharmacol Biochem Behav 1984 Nov;21(5):761–766 · descriptive/analytic · model: human plasma, human CSF, rabbit plasma, rat plasma, dog plasma · free DSIP confirmed in human CSF and plasma by gel chromatography and HPLC elution-position matching to synthetic DSIP; PMID: 6549071 ↩
doi:10.1210/jcem-59-1-127 · Graf MV, Hunter CA, Kastin AJ · J Clin Endocrinol Metab 1984 Jul;59(1):127–132 · descriptive/analytic · model: human breast milk (colostrum and mature milk) from 2 women · DSIP-like immunoreactivity: ~30 ng/mL colostrum, declining to ~10 ng/mL in mature milk; circadian variation (afternoon peak, morning trough); gel chromatography showed most immunoreactivity in colostrum and milk was in a form larger than the nonapeptide, but DSIP itself was confirmed by HPLC; PMID: 6547144 ↩
doi:10.1016/0306-4530(89)90004-8 · Bjartell A, Ekman R, Bergquist S, Widerlöv E · Psychoneuroendocrinology 1989;14(5):347–355 · n=11 healthy male volunteers (ages 25–39) · randomized double-blind crossover · 25 nmol/kg synthetic DSIP IV vs saline; significant reduction of ACTH-like immunoreactivity lasting ≥3 hours post-infusion; plasma cortisol levels unaffected; no differences in urinary cortisol or monoamine metabolites; PMID: 2554357 ↩ ↩²
PMID: 6895513 · Schneider-Helmert D, Gnirss F, Monnier M, Schenker J, Schoenenberger GA · Int J Clin Pharmacol Ther Toxicol 1981 Aug;19(8):341–345 · n=6 healthy volunteers (4 male, 2 female) · double-blind crossover, placebo-controlled · 25 nmol/kg IV (morning); sleep increased 59% (median total sleep time) vs placebo within 130 min; delayed effects: shorter sleep onset latency, reduced stage 1, better sleep efficiency; no sedation in the classic pharmacologic sense; compound well-tolerated, no psychological/physiological/biochemical side effects ↩ ↩²
doi:10.1007/BF01971753 · Schneider-Helmert D, Schoenenberger GA · Experientia 1981;37(9):913–917 · n=6 middle-aged chronic insomniacs · acute IV administration · 25 nmol/kg IV; longer sleep duration and higher quality with fewer interruptions; slightly more REM sleep; sleep-promoting effects from ~1–6 h post-injection; no daytime sedation or other side effects; PMID: 7028502; local PDF: not_oa ↩
PMID: 3583493 · Monti JM, Debellis J, Alterwain P, Pellejero T, Monti D · Int J Clin Pharmacol Res 1987;7(2):105–110 · n=not specified in abstract · double-blind crossover · 25 nmol/kg IV × 4 nights; decreased nocturnal awakenings, NREM latency, total waking time; increased total sleep and NREM (stage 2); no significant differences vs baseline or placebo for most measures; conclusion: “sleep improvement under DSIP treatment is of little clinical significance” ↩
doi:10.1159/000116143 · Schneider-Helmert D · Eur Neurol 1987;27(2):120–129 · n=14 middle-aged chronic insomniacs · double-blind, 7 successive nights · 25 nmol/kg IV; substantially improved night sleep with first and repeated doses; effects maintained into first post-treatment (placebo) night; alertness and mental performance at daytime increased significantly; sleep efficiency and daytime rest reached levels of normal controls; PMID: 3622582; local PDF: not_oa ↩
doi:10.1159/000118919 · Bes F, Hofman W, Schuur J, Van Boxtel C · Neuropsychobiology 1992;26(4):193–197 · n=16 chronic insomniacs · double-blind matched-pairs · 25 nmol/kg IV × 3 consecutive afternoons; higher sleep efficiency and shorter latency vs placebo; “statistically significant effects were weak”; no change in subjective sleep quality; conclusion: “not likely to be of major therapeutic benefit”; local PDF: not_oa ↩

🧬 Aging Wiki

Explorer

dsip